ARCHIVES

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

NIH Slow To Implement Equality In Studies, GAO Says, But Waxman Assures Reauthorization

June 22, 1990

IPRI’s Peter Boyle on Closing the Gap In Global Cancer Treatment And Outcomes

January 31, 2014

Copeland Named Director, UF Cancer Center

February 10, 1995

NCI CTEP: Approved Trials For The Month of October

October 28, 2011

Appropriators Ask What Happens After NIH Budget-Doubling Ends In FY2004.

May 25, 2001

NEJM Papers, Interview With NCI’s Doroshow, Provide Justification For Regulatory Action on ESAs.

June 15, 2007